CD274 and endometrial cancer: Notable targets among these which have demonstrated therapeutic significance when targeted in recent endometrial cancer clinical trials (Additional file 4: Figure S4) include programmed cell death protein 1 and programmed death-ligand 1 (PD-1/PD-L1) [10–12].